Friday, April 12, 2019 12:53:56 PM
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10.pdf
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10ex1.pdf
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10ex2.pdf
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10ex3.pdf
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10ex4.pdf
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10ex5.pdf
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10ex6.pdf
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10ex7.pdf
https://otcmarketresearch.com/wp-content/uploads/2019/04/LivingstonSRMX3a10ex8.pdf
The case already has the settlement offer ready to be approved just waiting on the court to set the hearing date to approve the settlement then Livingston Asset Management LLC (Stephen Hicks) will be able to start receiving discounted free trading stock to sell in tranches any time after that.
It's unfortunate to see SRMX going back down the 3(a)10 path again after all the dilution caused in 2018 by the eight 3(a)10 transactions done with Northbridge Financial Inc (Samuel Oshana)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139967202
On top of the new 3(a)10 transaction with Livingston Asset Management LLC (Stephen Hicks), SRMX disclosed in today's new Reg A filing that they sold about 1.5 billion free trading shares at $.0003/share through their previous Reg A offering (page F-10 in the subsequent events section):
https://www.sec.gov/Archives/edgar/data/841533/000168316819001007/saddleranch_253g2.htm
Now today's new offering for another 961,473,193 free trading shares to be sold at $.00024/share was a bit of a gut punch to retail investors
https://www.sec.gov/Archives/edgar/data/841533/000168316819001007/saddleranch_253g2.htm
Anyways, just wanted to share the documents for people to have access to them.
good luck
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM